KVA12123,Pembrolizumab
kineta bio,Merck
['biomarker']
$ka is surging by 23.50% today after kineta inc. presented promising vista biomarker data at the aacr annual meeting 2023 for cancer patients. #stockmarket #trading 
Stock Market Trader - Follow your own opinions